Image For Activity Cover
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF (JACC Heart Failure August 2022)

The HFC has developed a score integrating classes and doses of guideline-directed medical therapies prescribed for patients with heart failure (HF) and reduced ejection fraction. One potential use of this score is to test whether new treatments demonstrate incremental benefits, even in patients receiving comprehensive guideline-directed medical therapy.


JACC Heart Failure Editor-in-Chief
Biykem Bozkurt, MD, PhD, FACC 

Deputy Editor
Akshay S. Desai, MD, MPH 

JACC Heart Failure CME/MOC Editor
Kenneth A. Ellenbogen, MD

Brent C. Lampert, MD 

Important Dates

Date of Release: July 25, 2022
Term of Approval/Date of CME/MOC/ECME Expiration: July 24, 2023

Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered
Android App Download IOS App Download Powered By